Dongkook Pharmaceutical Reports 20 Billion KRW Operating Profit in Q2, Up 22.5% YoY

Exterior view of Dongkook Pharmaceutical headquarters.

[Asia Economy Reporter Lee Gwan-joo] Dongkook Pharmaceutical announced on the 16th that its consolidated operating profit for the second quarter reached 20 billion KRW, a 22.5% increase compared to the same period last year. During the same period, sales increased by 9.8% to 169.9 billion KRW.

For the first half of the year, sales amounted to 335.5 billion KRW and operating profit to 43.4 billion KRW, marking growth of 12.3% and 22.5% respectively compared to the previous year, achieving record-high sales for both the quarter and half-year periods.

By business division, all sectors including the OTC Division, Overseas Business Division, ETC Division, Healthcare Division, and subsidiary Dongkook Life Science showed balanced growth. In the OTC (over-the-counter) segment, demand increased for products such as the gum medicine Insadol Plus, wound treatment Madecassol, venous circulation improver Sensia, and oral hemorrhoid medicine Chisen, leading to sales growth compared to the previous year.

Exports also exceeded the first half target by 103%. Both raw materials and finished products of the glycopeptide antibiotic Teicoplanin showed steady growth across export regions including Brazil, Turkey, Spain, India, Bangladesh, Pakistan, and Japan. In the ETC (ethical drugs) segment, chronic disease medications such as the hyperlipidemia combination drugs Rosutanjet, Pitaron-F, and Atovanduo led growth. In the second half, the company plans to continuously strengthen its product lineup in the diabetes field with the launch of an oral diabetes treatment (DPP-4 Inhibitor drug).

The healthcare division is achieving balanced growth across all categories including cosmetics, health functional foods, medical devices, daily necessities, and pet products. In particular, the derma cosmetics brand 'Centellian24' is driving sales.

Subsidiary Dongkook Life Science also supported strong performance with stable growth of its key contrast agents such as Pamiray, Gadovision, Patiodol, and Duoray. Starting in the second half, the operation of the Anseong plant is expected to accelerate sales growth through vertical integration of manufacturing and distribution of active pharmaceutical ingredients (API) and finished pharmaceuticals.